Kimberly Maxfield, PhD, of the FDA reflected upon how the FDA is uplifting the US biosimilar industry.
Kimberly Maxfield, PhD, of the FDA explained how the FDA is uplifting the US biosimilar industry. Maxfield expanded upon the biosimilars topic during the AMCP Nexus session, "Biosimilar Operational Readiness: Marketplace Trends and Regulatory Considerations" on October 17.
At the FDA, Maxfield currently serves as the scientific lead on the Biosimilar User Fee Act (BsUFA) III regulatory research pilot program in the Office of Therapeutic Biologics and Biosimilars (OTBB).
Transcript
What do you wish more people understood about what the FDA is doing to uplift the US biosimilar industry?
The biosimilar lifecycle includes many pieces of the health care market and industry. We have the development, we have the marketing, we have the formulary access, we have the clinician comfort. FDA is purview in sort of that lifecycle, at the development phase, and in that education phase.
The regulatory science program is very focused on the time and cost of licensure, so it's very focused on the actual development program, the data package that's submitted as part of a 351(k) application.
However, the FDA is also doing a lot of educational efforts that are targeting patients, that are targeting providers, that are targeting pharmacists to inform them about what a biosimilar is and how it is different from a generic; that's just to increase comfort.
There's a lot of confusion between biosimilarity and interchangeability, and even in FDA's efforts to streamline the development process, we're never compromising on the statutory requirements or the safety and efficacy. Everything we're doing is trying to build on our experience, to build on others' experience. In the product quality information for biosimilars, every biosimilar and every interchangeable is exactly the same.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More